Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec departure
confidence 85%
filed 2026-07-21
Item 5.02
Kara Wilson, a director of Paychex, notified the Board on July 16, 2026 of her decision not to stand for re-election at the 2026 annual meeting, resulting in her departure from the Board. Although the departure is effective at the Annual Meeting (a future date), the principal disclosed action is a director's decision to leave office. The filing explicitly states the decision was not due to disagreement, and the Board's consequent reduction in size from 11 to 10 directors is a direct consequence of this departure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
CSB Bancorp issued a news release on July 21, 2026 announcing second quarter 2026 earnings results, with net income of $4,735,000 or $1.80 per diluted share (compared to $3,727,000 or $1.41 per share in Q2 2025), along with comprehensive financial tables and performance metrics. This is a standard quarterly earnings disclosure under Item 2.02, material to investors assessing the company's financial performance and profitability trends.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-21
Item 8.01
Nano Dimension announced termination of its corporate headquarters lease effective December 31, 2026, as part of ongoing cost savings initiatives. The transaction is expected to generate approximately $25 million in cumulative net cash savings through 2031 after accounting for a $13 million termination payment. This is a material operational restructuring decision that affects the company's real estate footprint and cash burn trajectory, but does not fit the specific categories of workforce_reduction, debt_issuance, or other named event types—it is a strategic operational/capital allocation decision disclosed under Item 8.01.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-07-21
Item 7.01
Onex Direct Lending BDC Fund disclosed quarterly portfolio and business commentary including NAV per share of $17.31 (down 7.7% from prior quarter of $18.75), net investment income, dividend information, portfolio composition, and leverage metrics, reflecting negative quarterly and year-to-date returns of -5.1% and -12.3% respectively.
View raw filing on EDGAR →
8-K
Financial Other
confidence 65%
filed 2026-07-21
Item 8.01
The filing disclosed NAV per share as of June 30, 2026 of $17.31 with aggregate NAV of $146.1 million and portfolio fair value of $287.8 million, along with status of an ongoing private offering showing 14.5 million shares issued for $359.8 million in total consideration.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-21
Item 2.02
Chubb Limited issued a press release on July 21, 2026 reporting its second quarter 2026 financial results, including net income of $2.85 billion ($7.30 per share), core operating income of $2.84 billion ($7.26 per share), and consolidated net premiums written of $14.7 billion. The disclosure includes detailed segment performance, combined ratios, investment income, and capital return information—all hallmarks of a quarterly earnings release. This is a material disclosure affecting investor assessment of the company's financial performance and operational results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-21
Item 5.07
This Item 5.07 discloses the results of Rein Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026, including voting outcomes on director elections (Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D.), approval of an amendment to increase authorized common shares from 100 million to 200 million, ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
AMERISAFE issued a press release on July 21, 2026, announcing its financial results for the second quarter ended June 30, 2026, disclosing net income of $14.6 million, diluted EPS of $0.78, and net premiums earned of $77.3 million with an 11.4% year-over-year increase. The press release is attached as Exhibit 99.1 and includes consolidated financial statements, detailed insurance and investment results, and management commentary—all hallmarks of a quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-21
Item 1.01
ACME United Corp entered into a new $65 million syndicated credit facility with HSBC and City National Bank on July 15, 2026, replacing its prior facility. The facility carries Term SOFR plus margin pricing, commitment fees, financial covenants, and a two-year maturity, representing a material creation of a direct financial obligation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-21
Item 1.02
The Company terminated a material definitive agreement as disclosed in Item 1.02, which incorporates Item 1.01 by reference.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-07-21
Item 1.01
Universal Health Services entered into a Twelfth Amendment to its Credit Agreement on July 20, 2026, establishing a new incremental delayed draw term loan facility of up to $700 million with a 364-day maturity for general corporate purposes including refinancing existing indebtedness.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-21
Item 2.01
The filing discloses completion of a disposition of a material asset—a net lease property sold for $2,475,000 with net proceeds of approximately $2.36 million. This is a direct application of Item 2.01 (Completion of Acquisition or Disposition of Assets), and the sale of a real property asset at this scale would materially affect a reasonable investor's assessment of the registrant's asset base and liquidity position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
WesBanco disclosed quarterly and six-month financial results for the period ended June 30, 2026, including net income of $88.4 million (Q2 2026) and $172.8 million (six months 2026), with diluted EPS of $0.91 and $1.79 respectively. The press release attached as Exhibit 99.1 presents comprehensive financial and operational highlights, balance sheet metrics, credit quality measures, and capital ratios—the hallmark of a standard earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-21
Item 3.02
EQT Private Equity Company LLC completed an unregistered sale of approximately 1.09 million shares across multiple share classes to third-party investors for aggregate cash consideration of $29.45 million as of July 1, 2026, under Section 4(a)(2) and Regulations D and S exemptions, with cumulative sales of $817.6 million since inception.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-07-21
Item 8.01
The disclosure centers on two capital allocation actions: (1) an $800 million increase to the share repurchase program (bringing total authorization to $2.5 billion through Dec. 31, 2029) and (2) declaration of a quarterly cash dividend of $0.339 per share payable August 19, 2026. While both are disclosed, the dividend declaration is the more concrete and immediate commitment, whereas the repurchase authorization is discretionary and non-binding. The event is material as it reflects the company's capital allocation strategy and shareholder return policy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-07-21
Item 1.01
Finward Bancorp entered into an Agreement and Plan of Merger with First Financial Bancorp on July 21, 2026, whereby Finward will merge into First Financial in an all-stock transaction valued at approximately $208 million (1.35 shares of First Financial per Finward share). The transaction is expected to close in Q4 2026 and requires shareholder approval and regulatory clearance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
James Beecham was appointed as a Class I Director to Aware Inc's Board of Directors on July 15, 2026, upon recommendation of the Nominating and Corporate Governance Committee.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-21
Item 5.07
Aware Inc held its Annual Meeting of Shareholders on July 15, 2026, with final voting results reported on four matters: election of Class III directors (Amlani and Faubert), advisory approval of named executive officer compensation, ratification of RSM US LLP as independent auditor, and approval of a 1,000,000-share increase to the 2023 Equity and Incentive Plan.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-21
The 8-K discloses the issuance of $10 billion in fixed-to-floating rate notes across three tranches (2032, 2037, and 2057 maturities) by Goldman Sachs on July 21, 2026, pursuant to its shelf registration statement. This represents a material creation of direct financial obligations and is a classic debt issuance event under Item 9.01.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 80%
filed 2026-07-21
Item 8.01
M&T Bank completed a public offering of 24,000,000 depositary shares representing interests in newly established Series L Preferred Stock on July 21, 2026. The preferred stock carries fixed dividend obligations and redemption rights, functioning as a debt-like financial obligation. This material capital-raising transaction was effected through a certificate of amendment to the articles of incorporation and an underwriting agreement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-21
Item 5.02
Jonathan E. Benfield was appointed Chief Financial Officer of CrossAmerica GP LLC, the general partner, effective immediately on July 20, 2026, transitioning from his interim role since March 2, 2026.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-21
Item 7.01
The Board approved a quarterly distribution of $0.5250 per unit attributable to Q2 2026 (annualized $2.10 per unit), payable August 13, 2026 to unitholders of record on August 3, 2026.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-07-21
Item 1.01
Nano Dimension executed a settlement agreement with activist investor Murchinson resulting in the resignation of four directors (Pons, Stehlin, Rosensweig, Sriubas) and appointment of three Murchinson-nominated directors (Fruchthandler, Rozenbaum, Tarlow), constituting a material board reconstitution and change of control. The settlement also resulted in cancellation of a scheduled extraordinary general meeting.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-21
Item 3.02
EQT Infrastructure Company LLC completed an unregistered sale of approximately 3.9 million equity shares across multiple classes to third-party investors for aggregate consideration of $106.2 million as of July 1, 2026, under Section 4(a)(2) and Regulations D and S. Since inception on February 1, 2026, the Company has sold approximately $817.6 million of Investor Shares as part of its continuous private offering.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-21
Item 1.01
Nuburu closed a $38.0 million public offering on July 17, 2026, issuing 117.4 million shares of common stock, 127.0 million pre-funded warrants, and 733,853 shares of Series B Preferred Stock convertible into 205.6 million additional common shares. The offering materially dilutes existing shareholders' ownership and voting power, with proceeds intended for the Tekne acquisition and debt retirement.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-21
Item 3.01
On July 17, 2026, Nuburu received a delisting notice from NYSE American because its common stock traded below $0.10, violating Section 1003(f)(v) of the NYSE American Company Guide. The company intends to appeal and implement a reverse stock split to regain compliance.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-07-21
EX-99.1
Docebo announces the commencement of a substantial issuer bid (share repurchase program) to repurchase up to 3,431,372 common shares at US$20.40 per share for an aggregate price not exceeding US$70,000,000. Share repurchases are a form of return of capital to shareholders and fall within the dividend_distribution category, which encompasses share-repurchase programs. The materiality is clear given the significant dollar amount (US$70 million) and the scale of the repurchase relative to the company's market capitalization.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-21
EX-99.1
This exhibit is a press release announcing Birks Group's fiscal 2026 financial results for the year ended March 28, 2026. It discloses net sales of $205.4 million (up 15.5%), gross profit of $79.2 million, operating income of $3.1 million, and net loss of $3.4 million ($0.17 per share), along with consolidated statements of operations and balance sheets. The disclosure is material as it reports annual financial performance and would affect a reasonable investor's assessment of the company's financial condition and results.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-21
EX-99.1
This exhibit is a press release announcing a strategic partnership between Rezolve Ai and Zilch, a major UK fintech platform serving nearly 6 million customers and driving $3.3 billion annually in merchant transactions. The partnership embeds Rezolve Ai's Reward platform into Zilch's payments experience. While not a discrete M&A transaction, this is a material operational and strategic business development—a significant commercial partnership with a high-profile fintech unicorn that the company explicitly cites as validation of its strategy and reinforcement of FY26 revenue guidance of approximately $360 million. The disclosure emphasizes the partnership's scale and strategic importance to Rezolve Ai's positioning as an AI commerce infrastructure provider.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-21
Item 1.02
Evolution Malta Holding Limited terminated the Agreement and Plan of Merger dated July 18, 2024 with Galaxy Gaming. Galaxy will receive a $5.2 million termination fee as a result of the merger agreement termination.
View raw filing on EDGAR →
8-K
Cybersecurity Incident
confidence 85%
filed 2026-07-21
Item 8.01
The filing discloses a cybersecurity incident involving unauthorized access to "certain non-sensitive customer information and other documents" that was subsequently used to facilitate fraudulent lease-to-own agreements, resulting in approximately $13 million in fraudulent contract losses in the Acima segment during Q2 2026. Although the Company states it "believes that the incidents are not material" based on current knowledge, the quantified financial impact ($13M in losses), the involvement of federal law enforcement notification, and the implementation of significant remediation measures (enhanced authentication, fraud detection capabilities) indicate a material cybersecurity incident under Item 1.05 standards. The $13 million loss impact alone is material to a reasonable investor's assessment of the registrant's financial condition and operational risk.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-21
Item 2.02
Southern First Bancshares issued a press release on July 21, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing net income of $11.2 million, diluted EPS of $1.20 (up 48% year-over-year), and strong operational metrics including 28% net interest income growth and 9% annualized loan growth.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-07-21
EX-99.1
This is a CEO letter that includes a "Preliminary First Half 2026 Financial Update" disclosing revenue of approximately $0.9 million for H1 2026 (down from $1.07 million in H1 2025) and cash position of $7.7 million as of June 30, 2026. Although framed as a strategic letter rather than a formal earnings press release, it furnishes preliminary financial results for the first half of 2026 and would be material to investors assessing the company's financial performance and cash runway. The disclosure of declining revenue and cash position, combined with management's acknowledgment of share-price volatility and need to "strengthen our balance sheet," signals material financial information that affects investor assessment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-21
Jack Mallers resigned as CEO and director effective July 20, 2026, with a separation agreement providing cash payments and vested equity. While the filing also discloses Raphael Zagury's appointment as CEO, the principal disclosed action centers on Mallers' departure—the triggering event that necessitated the leadership transition. The departure is material to a reasonable investor assessing the registrant's leadership continuity.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-21
EX-99.1
PolyPid has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for D-PLEX100 commercialization in the U.S. and Canada. The agreement involves substantial financial consideration ($30 million upfront and near-term, plus up to $300 million in milestone payments and tiered royalties), transfer of commercial rights, and manufacturing obligations. This constitutes a material disposition of commercial rights and a significant strategic transaction that would affect a reasonable investor's assessment of the company's value and future revenue streams.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-21
Item 7.01
Planet Green's subsidiary Shanghai Shuning entered into a comprehensive digital marketing services contract with iFLYTEK running through December 2026. The press release emphasizes this as a "significant milestone" and "significant new marketing contract" that "significantly strengthens our revenue pipeline" and positions the company as a premier service provider for tier-one technology clients. While this is a material business development event for the company's digital marketing segment, it does not fit neatly into the specific event-type taxonomy (not M&A, not a material impairment, not a restructuring). It is clearly operational in nature—a new material contract win—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-21
Item 5.02
Constantine Dakolias was appointed as a director and audit committee member of Bleichroeder Acquisition Corp. III effective July 20, 2026. The disclosure centers on the appointment of a qualified independent director with extensive investment and credit management experience, making this a clear executive appointment event material to investors evaluating the company's governance and board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-21
Item 5.02
The filing discloses the Board's nomination of Mr. Ng Tsze Lun for election as a director and his appointment as Chairman of the Board effective after stockholder approval at the 2026 annual meeting. While the filing also mentions Mr. Choi Lin Hung's decision not to stand for re-election as director and Chairman, the principal disclosed action centers on the appointment of Mr. Ng to the Chairman role. The press release reinforces this as a "Board Leadership Transition" with Mr. Ng succeeding Mr. Choi as Chairman, making the appointment the salient event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-21
EX-99.1
This is a monthly operational and production update disclosing material business metrics and strategic developments: Bitcoin production increased 388% Y/Y to 990 BTC, AI Cloud ARR grew to ~$76M at 95% utilization, self-mining hashrate reached 73.0 EH/s, and the company announced groundbreaking of a Sealminer manufacturing facility in Nevada and execution of a 10-year lease for 21.7 IT MW in Malaysia. These operational milestones and capacity expansions would materially affect a reasonable investor's assessment of the company's growth trajectory and infrastructure development, though the disclosure is operational rather than financial results, M&A, or governance in nature.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-21
Item 8.01
The filing discloses two operational developments: (1) preparation and filing of investor presentation materials outlining the Company's three technology platforms and strategic direction, and (2) announcement of a joint venture with Placeve Inc. via press release. While the presentation materials are routine corporate communications, the joint venture announcement represents a material strategic partnership that would affect a reasonable investor's assessment of the Company's operational direction and growth strategy. This is an operational/strategic event that does not fit the specific categories of M&A activity, debt issuance, or other named types, making operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-21
EX-99.1
This press release announces positive clinical trial results for Alpha DaRT in combination with pembrolizumab in head and neck cancer, demonstrating a 100% objective response rate and 18.2-month median overall survival that exceed pre-specified thresholds and historical benchmarks. While the disclosure reports clinical progress rather than a discrete corporate event (M&A, executive change, debt issuance, etc.), the achievement of a major clinical milestone with favorable efficacy and safety data in a key indication materially advances the company's pipeline and regulatory strategy, directly supporting its stated plan to pursue larger U.S. studies in discussion with the FDA.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-21
Cadrenal announced a comprehensive strategic realignment of its clinical portfolio into a "Cardiac Acute Critical Care Franchise" and initiated a structured process to secure out-licensing, portfolio monetization, or commercial co-development partnerships for late-stage assets. This represents a material shift in the company's business model and operational strategy—from internal development to a partnership-driven model—which would affect a reasonable investor's assessment of the company's path to commercialization and capital efficiency. While the filing does not disclose a completed M&A transaction or specific partnership agreement, the strategic portfolio reorganization and active partnering process constitute a material operational and strategic business event.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-21
Item 5.03
Change Agents Corporation (formerly Avalon GloboCare Corp.) completed a corporate name change and corresponding Nasdaq ticker symbol change from ALBT to CHGA, effective July 22, 2026. The name and symbol change reflects the company's strategic repositioning and is material to investors as it affects trading identification, though no stockholder approval was required and the change does not affect stockholder rights.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-21
Item 1.01
Virtuix amended three warrants to reduce the exercise price from $3.00 to $2.50 per share during a specified period (July 21 – August 27, 2026), making the warrants more likely to be exercised and diluting existing shareholders. While technically an amendment to existing warrants rather than a new issuance, the material reduction in exercise price substantially increases the probability of dilution and is economically equivalent to a dilutive capital event. The filing under Item 1.01 (Material Definitive Agreement) and the involvement of a significant investor (Streeterville Capital) underscore materiality.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-07-21
The 6-K discloses a change in ticker symbol from YOOV to CIGL, effective July 21, 2026, on the Nasdaq Capital Market. While a ticker change alone is not necessarily a delisting event, it often signals a transfer of listing or a change in market tier (e.g., from Nasdaq Global Market to Nasdaq Capital Market, or vice versa). The disclosure of a "new ticker symbol" and the specific effective date suggest a material change in the registrant's listing status that would affect investor identification and trading of the security.
View raw filing on EDGAR →
6-K
M&A activity
confidence 85%
filed 2026-07-21
EX-99.1
SuperX announced a strategic partnership with Mercuria Asia involving a material investment through a convertible note and warrant subscription agreement. While structured as a "partnership" rather than a traditional acquisition or merger, the convertible note and warrant issuance represents a significant capital transaction and equity dilution that would materially affect investor assessment. The press release emphasizes this as a "significant milestone in SuperX's global expansion" with long-term strategic implications for the company's infrastructure development and profitability.
View raw filing on EDGAR →
6-K
Governance Other
confidence 92%
filed 2026-07-21
The 6-K discloses a series of voluntary corporate governance enhancements by Charming Medical's board, including: (1) a lock-up agreement by majority shareholder and CEO Ms. Kit Wong restricting share sales for one year; (2) the company's election to abandon foreign private issuer exemptions and comply fully with Nasdaq domestic governance standards; and (3) the irrevocable surrender and cancellation of all Class B Ordinary Shares (held by Ms. Wong), eliminating the dual-class voting structure and reducing her voting power from ~91.25% to ~68.19%. These measures materially affect shareholder governance rights and the company's capital structure and listing compliance posture.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-21
The 6-K discloses the appointment of Mr. Nazario Matachione as a member of the Board of Directors of RoyaLand Company, Ltd. effective July 16, 2026. The filing explicitly states "the Board of Directors of The RoyaLand Company, Ltd. (the "Company") appointed Mr. Nazario Matachione as a member of the Board" and provides extensive biographical detail on his qualifications and experience. This is a clear executive appointment to the board, material to investors assessing the company's governance and leadership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-07-21
Item 7.01
The filing discloses results of a shareholder vote at an annual meeting held on July 21, 2026, where shareholders approved all proposals including an amendment to extend the SPAC's deadline to complete an initial business combination. This is a direct disclosure of shareholder vote results under Item 5.07, and the extension approval is material to investors as it affects the timeline and viability of the proposed business combination with a critical mineral target company announced on July 17, 2026.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-21
EX-99.1
This press release announces a follow-on order for ParaZero's DefendAir Pods for integration into an autonomous Counter-UAS operational system protecting critical infrastructure. The disclosure is a business development event—a material customer order—that does not fit the specific event-type taxonomy (not M&A, not a financial obligation, not a results announcement). It is clearly operational in nature, reflecting commercial traction and market validation for the company's core product line, and would be material to a reasonable investor assessing the company's revenue prospects and market adoption.
View raw filing on EDGAR →